Non-steroidal glucocorticoid receptor antagonists: the race to replace RU-486 for anti-glucocorticoid therapy

Bibliography

• HEIKINHEIMO O, RANTA S, GRUNBERG S, LAHTEENMAKI P, SPITZ IM: Alterations in the pituitary-thyroid and pituitary-adrenal axes – consequences of long-term mifepristone treatment. Metabolism (1997) 46(3):292-296.
   PubMed Web of Science ®Google Scholar
• GEBHARD R, VAN DER VOORT H, SCHUTS W, SCHOONEN W: 11,21-Bisphenyl-19-norpregnane derivatives are selective anti-glucocorticoids. Bioorg. Med. Chem. Lett. (1997) 7(17):2229-2234.
   Web of Science ®Google Scholar
• THOMSON F, CRAIGHEAD MW, WATSON L, TURNBULL Z, MCINTOSH L, SPEAKE M: European Neuropsychopharmacology (2003) 13:S229
   Google Scholar
• CHU JW, MATTHIAS DF, BELANOFF J, SCHATZBERG A, HOFFMAN AR, FELDMAN D: Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486). J. Clin. Endocrinol. Metab. (2001) 86(8):3568-3573.
   PubMed Web of Science ®Google Scholar
• SONG IH, GOLD R, STRAUB RH, BURMESTER GR, BUTTGEREIT F. New glucocorticoids on the horizon: repress, don't activate! J. Rheumatol. (2005) 32(7):1199-1207.
   Web of Science ®Google Scholar
• BELVISI MG, WICK SL, BATTRAM CH: Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J. Immunol. (2001) 166:1975-1982.
   PubMed Web of Science ®Google Scholar
• VAYSSIERE BM, DUPONT S, CHOQUART A: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol. Endocrinol. (1997) 11:1245-1255.
   PubMed Web of Science ®Google Scholar
• GUMS JG, SMITH JD: Chapter 72: adrenal gland disorders. In: Pharmacotherapy: A Pathophysiologic Approach, Fourth Edition. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (Eds). Appleton & Lange, Stamford, CT (1999) 1267-1273.
   Google Scholar
• CUSHING HW: The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull. Johns Hopkins Hosp. (1932) 50:138-195.
   Google Scholar
• MEDVEI VC: The history of Cushing’s disease: a controversial tale. J. Royal Soc. Med. (1991) 84:363-366.
   Google Scholar
• BISHOP PMF, CLOSE HG: A case of basophil adenoma of the anterior lobe of the pituitary: “Cushing’s syndrome”. Guy’s Hosp. Rep. (1932) 82:143-153.
   Google Scholar
• JORES A: Ueber Hormonuntersuchungen bei Morbus Cushing. Klin. Wochenschr. (1945) 14:1348-1352.
   Google Scholar
• ALBRIGHT F, PARSON W, BLOOMBERG E: Cushing’s syndrome interpreted as hyperadrenocorticism leading to hypergluconeogenesis: results of treatment with testosterone propionate. J. Clin. Endocrinol. (1941) 1:375-381.
   Google Scholar
• BEAUREGARD C, DICKSTEIN G, LACROIX A: Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy. Treat. Endocrinol. (2002) 1(2):79-94.
   PubMedGoogle Scholar
• WISNIEWSKI AB, BROWN TT, JOHN M et al.: Cortisol levels and depression in men and women using heroin and cocaine. Psychoneuroendocrinology (2006) 31(2):250-255.
   PubMed Web of Science ®Google Scholar
• KLING MA, DEMITRACK MA, WHITFIELD HJ: Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients. Neuroendocrinology (1993) 57(6):1082-1091.
   PubMed Web of Science ®Google Scholar
• O'BRIEN RM, NOISIN EL, SUWANICHKUL A et al.: Hepatic nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein 1 genes. Mol. Cell. Biol. (1995) 15(3):1747-1758.
   PubMed Web of Science ®Google Scholar
• JANTZEN HM, STRÄHLE U, GLOSS B et al.: Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene. Cell (1987) 49(1):29-38.
   PubMed Web of Science ®Google Scholar
• GRENIER J, TOMKIEWICZ C, TROUSSON A et al.: Identification by microarray analysis of aspartate aminotransferase and glutamine synthetase as glucocorticoid target genes in a mouse Schwann cell line. J. Steroid Biochem. Mol. Biol. (2005) 97(4):342-352.
   Google Scholar
• GETTYS TW, WATSON PM, TAYLOR IL, COLLINS S: RU-486 (Mifepristone) ameliorates diabetes but does not correct deficient β-adrenergic signaling in adipocytes from mature C57BL/6J-ob/ob mice. Int. J. Obes. Relat. Metab. Disord. (1997) 21(10):865-873.
   PubMed Web of Science ®Google Scholar
• TWARDOWSKA K, RYBAKOWSKI J: Limbic-hypothalamic-pituitary-adrenal axis in depression: literature review. Psychiatr. Pol. (1996) 30(5):741-755.
   Google Scholar
• DEBATTISTA C, BELANOFF J: The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrinol. Metab. (2006) 17(3):117-121.
   PubMed Web of Science ®Google Scholar
• WISNIEWSKI AB, BROWN TT, JOHN M et al.: Cortisol levels and depression in men and women using heroin and cocaine. Psychoneuroendocrinology (2006) 31(2):250-255.
   PubMed Web of Science ®Google Scholar
• KLING MA, DEMITRACK MA, WHITFIELD HJ: Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients. Neuroendocrinology (1993) 57(6):1082-1091.
   PubMed Web of Science ®Google Scholar
• POMARA N, GREENBERG WM, BRANFORD MD, DORAISWAMY PM: Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and update. Psychopharmacol. Bull. (2003) 37(2):120-134.
   PubMedGoogle Scholar
• REGELSON W: RU-486: how abortion politics have impacted on a potentially useful drug of broad medical application. Perspect. Biol. Med. (1992) 35(3):330-338.
   Google Scholar
• WOLKOWITZ OM, REUS VI: Treatment of depression with antiglucocorticoid drugs. Psychosom. Med. (1999) 61(5):698-711.
   PubMed Web of Science ®Google Scholar
• BUETTI E, KÜHNEL B: Distinct sequence elements involved in the glucocorticoid regulation of the mouse mammary tumor virus promoter identified by linker scanning mutagenesis. J. Mol. Biol. (1989) 190:379-389.]
   Google Scholar
• MORGAN BP, SWICK AG, HARGROVE AM et al.: Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J. Med. Chem. (2002) 45:2417-2424.
   PubMed Web of Science ®Google Scholar
• CHU J, MATTHIAS DF, BELANOFF J, SCHATZBERG A, HOFFMAN AR, FELDMAN D: Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU-486). J. Clin. Endocrinol. Metab. (2001) 86(8):3568-3573.
   PubMed Web of Science ®Google Scholar
• LIU K: Proceedings of the 222nd American Chemical Society National Meeting. Chicago, USA (2001) MEDI-169.
   Google Scholar
• MINER JN, TYREE C, HU J et al.: A nonsteroidal glucocorticoid receptor antagonist. Mol. Endocrin. (2003) 17:117-127.
   PubMed Web of Science ®Google Scholar
• COGHLAN MJ, ELMORE SW, KYM PR, KORT ME: Chapter 17. Selective glucocorticoid receptor modulators. Annu. Rep. Med. Chem. (2002) 37:167-178.
   Google Scholar
• LINK JT, SORENSEN BK, PATEL J et al.: Discovery of novel nonsteroidal glucocorticoid receptor modulators. Bioorg. Med. Chem. Lett. (2004) 14:2209-2212.
   Google Scholar
• LINK JT, SORENSEN B, PATEL J et al.: Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators. J. Med. Chem. (2005) 48(16):5295-5304.
   PubMed Web of Science ®Google Scholar
• NEEL DA, BROWN ML, LANDER PA et al.: 3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15(10):2553-2557.
   PubMed Web of Science ®Google Scholar
• BETAGERI R, ZHANG Y, ZINDELL RM et al.: Trifluoromethyl group as a pharmacophore: effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand. Bioorg, Med. Chem. Lett. (2005) 15:4761-4769.
   Google Scholar
• MACDIARMID F, WANG D, DUNCAN LJ, PUROHIT A, GHILCHICK MW, REED MJ: Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor α. Mol. Cell. Endocrinol. (1994) 106(1-2):17-21.
   PubMed Web of Science ®Google Scholar
• AKRITOPOULOU-ZANZE I, PATEL JR, HARTANDI K et al.: Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. (2004) 14:2079-2082.
   Google Scholar
• DOGGRELL SA: Is AL-438 likely to have fewer side effects than the glucocorticoids? Expert Opin. Invest. Drugs (2003) 12(7):1227-1230.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, BEKKALI Y, CAPOLINO AJ et al.: Discovery and SAR study of novel dihydroquinoline containing glucocorticoid receptor ligands. Bioorg. Med. Chem. Lett. (2006) 16(6):1549-1552.
   Google Scholar
• HIRSCHMANN R, STEINBERG NG, BUCHSCHACHER P et al.: Synthesis and structure of steroidal 4-pregneno [3,2-c]pyrazoles. A novel class of potent anti-inflammatory steroids. J. Amer. Chem. Soc. (1963) 85(1):120-122
   Web of Science ®Google Scholar
• DAVIES S, DAI D, PICKETT G, LESLIE KK: Gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa H cells. Gynecol. Oncol. (2006) 101(1):62-70.
   Google Scholar
• HONER C, NAM K, FINK C et al.: Glucocorticoid receptor antagonism by cyproterone acetate and RU-486. Mol. Pharmacol. (2003) 63(5):1012-1020.
   PubMed Web of Science ®Google Scholar
• WEBB P, NGUYEN NH, CHIELLINI G et al.: Design of thyroid hormone receptor antagonists from first principles. J. Steroid Biochem. Mol. Biol. (2002) 83(1-5):59-73.
   PubMed Web of Science ®Google Scholar
• BRZOZOWSKI AM, PIKE AC, DAUTER Z et al.: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 389:753-758.
   PubMed Web of Science ®Google Scholar
• KAUPPI B, JAKOB C, FARNEGARDH M et al.: The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. (2003) 278(25):22748-22754.
   PubMed Web of Science ®Google Scholar
• SHIAU AK, BARSTAD D, RADEK JT et al.: Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. (2002) 9(5):359-364.
   PubMedGoogle Scholar
• VON GELDERN TW, TU N, KYM PR et al.: Liver-selective glucocorticoid antagonists: a novel treatment for Type 2 diabetes. J. Med. Chem. (2004) 47:4213-4230.
   Google Scholar
• JACOBSON PB, VON GELDERN TW, OHMAN L et al.: Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of Type 2 diabetes. J. Pharmacol. Exp. Ther. (2005) 314:191-200.
   PubMed Web of Science ®Google Scholar